Daily Market Alert

    Strong Buy Stocks for Friday, November 20, 2026: Five Names Riding Thursday's Analyst Upgrades

    Friday, November 20, 2026

    These are the five stocks to watch heading into Friday, November 20, 2026. Each received a bullish rating change or new coverage that circulated on Thursday, November 19. On Wednesday, November 18, the S&P 500 fell 16.90 points, or 0.2%, to 7,323.63, its fifth straight loss. The Dow Jones Industrial Average dropped 561.25 points, or 1.1%, to 50,198.17, while the Nasdaq Composite rose 101.50 points, or 0.4%, to 24,429.88. On November 19, Anthropic opened shortly before noon ET at $111.50, about 34% above its $83.00 IPO price, yet major indexes slid to session lows. Around 1:45 p.m. ET, the S&P 500 and Nasdaq were each down about 1.3%, and the Dow was off 817 points. Walmart reported adjusted EPS of $0.65 on revenue of $188.84 billion before the open on November 19 and raised its full-year sales outlook.

    The five ideas below span medical technology, automotive semiconductors, chip design software, life reinsurance, and insurance brokerage. Editorial notes only, not investment advice.

    πŸ“’ Sponsor Slot β€” rotating content will appear here

    Abbott Laboratories (ABT) – Leerink Upgrades the Diversified Medtech Leader

    Leerink Partners analyst Mike Kratky upgraded Abbott to Outperform from Market Perform and raised his target to $124.00 from $106.00. He wrote that "the current risk/reward setup leans squarely positive," citing better-than-expected data updates and a valuation of about 17.8 times forward earnings, below its five-year average of about 22.4 times. In our view, medtech could attract money rotating out of crowded AI trades.

    Shares traded near $103.87 during Thursday's session, down about 0.6%, giving Abbott a market capitalization near $179.90 billion. The 52-week range runs from $81.97 to $129.85, the trailing P/E is about 38.5, and the dividend yield is near 2%.

    Consensus reads strong buy, with all 20 tracked firms bullish. The average target of $123.15 implies about 18.6% upside, while Leerink's target implies about 19.4%. Wells Fargo's Larry Biegelsen raised his target to $120.00 from $119.00 on October 23.

    Risks: The stock had fallen about 16.6% from the start of 2026 through November 18, and Argus downgraded it to Hold on October 27. Guidance follow-through remains a factor to monitor.

    NXP Semiconductors (NXPI) – StoneX Initiates the Automotive Chip Specialist

    StoneX analyst Gary Mobley started coverage of NXP at Buy with a $340.00 target in a note released late on November 18. He called NXP one of the "cleanest ways to play the broadening chip cycle without taking risk from the growing concerns surrounding the AI data center trade." Data center sales are under 5% of expected fiscal 2026 revenue, and StoneX sees software-defined vehicle processors driving growth. In our view, that profile offers chip exposure with less dependence on AI spending.

    Shares traded near $255.19 during Thursday's session, up about 1.1%, giving NXP a market capitalization near $64.32 billion. The 52-week range spans $183.00 to $339.95, and the trailing P/E is about 20.1.

    Consensus reads buy, with 11 of 20 tracked firms bullish and 1 bearish. The average target of $294.40 implies about 15.4% upside, while StoneX's target implies about 33.2%. Jefferies' Blayne Curtis kept a Buy rating but trimmed his target to $350.00 from $370.00 on October 28.

    Risks: StoneX's margin case depends on new 300-millimeter factories coming online, with gross margins potentially reaching 60% in 2027. Auto production cycles remain a factor to monitor.

    Synopsys (SNPS) – Barclays Initiates the Chip Design Software Leader

    Barclays analyst Saket Kalia initiated Synopsys at Overweight with a $640.00 target. He highlighted its top share in electronic design automation, a duopoly serving the $1.5 trillion semiconductor industry, which the firm called "one of the more attractive competitive landscapes in software." Barclays based its target on 23 to 24 times fiscal 2030 free cash flow. In our view, Synopsys benefits from chip design spending regardless of which chipmakers win.

    Shares traded near $434.61 during Thursday's session, up about 0.1%, giving Synopsys a market capitalization near $83.29 billion. The 52-week range runs from $362.55 to $539.48, and the trailing P/E is about 76.8.

    Consensus reads strong buy, with 15 of 16 tracked firms bullish and 1 bearish. The average target of $587.44 implies about 35.2% upside, while Barclays' target implies about 47.3%. Needham's Charles Shi raised his target to $620.00 from $580.00 on October 12.

    Risks: The trailing multiple is steep, and the Barclays thesis leans on fiscal 2030 projections. Chip research budgets and Ansys integration remain factors to monitor.

    Reinsurance Group of America (RGA) – UBS Upgrades the Life Reinsurer

    UBS analyst Michael Ward upgraded RGA to Buy from Neutral and raised his target to $325.00 from $236.00, citing "durable earnings strength." UBS expects improving mortality, aided by wider GLP-1 use, to lift claims experience. The firm also sees understated earnings power in a block acquired from Equitable. In our view, low market sensitivity adds a defensive quality.

    Shares traded near $267.98 during Thursday's session, up about 0.9%, giving RGA a market capitalization near $17.43 billion. The stock sits near the top of its 52-week range of $184.34 to $277.15, with a trailing P/E of about 10.4.

    Consensus reads strong buy, with 7 of 9 tracked firms bullish and none bearish. The average target of $283.44 implies only about 5.8% upside, so UBS's target, about 21.3% higher, better reflects the bull case. Wells Fargo's Wesley Carmichael raised his target to $312.00 from $292.00 on November 12.

    Risks: Mortality trends can reverse, and the Equitable block adds integration risk. TD Cowen's Hold rating and the stock's proximity to its high remain factors to monitor.

    Marsh McLennan (MRSH) – Wells Fargo Upgrades the Insurance Broker

    Wells Fargo analyst Elyse Greenspan upgraded Marsh McLennan to Overweight from Equal Weight and raised her target to $235.00 from $197.00. Wells Fargo wrote, "We see 2027 EPS upside from AltamarCAM and Wilshire acquisitions." It downgraded Aon and Arthur J. Gallagher in the same review. In our view, the relative call matters as much as the upgrade.

    Shares traded near $204.93 during Thursday's session, down about 0.3%, giving Marsh McLennan a market capitalization near $97.79 billion. The 52-week range spans $156.60 to $214.00, and the trailing P/E is about 24.5.

    Consensus reads buy, with 8 of 15 tracked firms bullish and 1 bearish. The average target of $212.07 implies about 3.5% upside, while Wells Fargo's target implies about 14.7%. Morgan Stanley's Bob Huang raised his target to $215.00 from $190.00 on November 16 but kept an Equal-Weight rating.

    Risks: Neutral ratings make up 40% of coverage, and the acquisition benefits are a 2027 estimate, not a result. Insurance pricing and deal integration remain factors to monitor.

    Found this helpful? Share it with others.

    Our Flagship Publication

    Discover Great Companies Trading at a Discount

    Join Behind the Markets